The Effects of Loading Ranibizumab on Vision-related Quality of Life in the Treatment of Low-risk Neovascular Age-related Macular Degeneration

Overview

Journal Ther Adv Ophthalmol

Specialty Ophthalmology

Date 2022 Jul 25

PMID 35873278

Authors

Hatice Daldal

Affiliations

Soon will be listed here.

Abstract

Background: The loss of central vision plays a major role in the quality of life (QoL). This study evaluates the changes in QoL in the treatment of low-risk neovascular age-related macular degeneration (AMD).

Objectives: The aim of this study was to evaluate the changes in vision-related QoL in patients receiving intravitreal ranibizumab loading dose for low-risk neovascular AMD.

Design: A prospective study.

Methods: Forty-two eyes of 42 patients receiving ranibizumab injections for neovascular AMD were included in this prospective study. The changes in best-corrected visual acuity (BCVA), central macular thickness (CMT) of the patients before the treatment, and 1 month after three loading doses were evaluated. Turkish version of the National Eye Institute 25-Item Vision Function Questionnaire (NEI VFQ-25 TR) was conducted. The changes of QoL scores through the NEI VFQ-25 TR questionnaire were compared with visual acuity (VA) and CMT measurements before the injections and 1 month after the loading dose.

Results: Forty-two patients (19 females and 23 males) were included in the study, and the mean age was 72.69 ± 7.12 years. After the treatment, a statistically significant improvement in BCVA (0.98 ± 0.44, 0.76 ± 0.42 logMAR, < 0.001) and a significant decrease in CMT (357.90 ± 71.71, 274.50 ± 58.35 μm, < 0.001) was observed. The QoL composite score was found to be statistically significantly higher after the treatment (64.27 ± 11.47, 68.56 ± 11.39, < 0.001). General vision ( < 0.001), ocular pain ( = 0.025), near activities ( < 0.001), distance activities ( = 0.027), vision-specific mental health ( = 0.014), vision-specific role difficulties ( < 0.001), and peripheral vision ( = 0.046) were significantly higher after the treatment.

Conclusion: NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections.

References

Rasmussen A, Brandi S, Fuchs J, Hansen L, Lund-Andersen H, Sander B . Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration. Acta Ophthalmol. 2015; 93(7):616-20. DOI: 10.1111/aos.12781. View

Bressler N, Chang T, Fine J, Dolan C, Ward J . Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol. 2009; 127(1):13-21. DOI: 10.1001/archophthalmol.2008.562. View

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

Brown M, Brown G, Sharma S, Stein J, Roth Z, Campanella J . The burden of age-related macular degeneration: a value-based analysis. Curr Opin Ophthalmol. 2006; 17(3):257-66. DOI: 10.1097/01.icu.0000193079.55240.18. View

Karacorlu M, Hocaoglu M, Arf S, Ersoz M, Sayman Muslubas I . Risk-based Algorithm-guided Treatment Protocol for the Management of Neovascular Age-related Macular Degeneration. Turk J Ophthalmol. 2019; 49(5):258-269. PMC: 6823591. DOI: 10.4274/tjo.galenos.2019.26235. View

Mangione C, Lee P, Gutierrez P, Spritzer K, Berry S, Hays R . Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001; 119(7):1050-8. DOI: 10.1001/archopht.119.7.1050. View

Guyer D, Fine S, Maguire M, Hawkins B, Owens S, Murphy R . Subfoveal choroidal neovascular membranes in age-related macular degeneration. Visual prognosis in eyes with relatively good initial visual acuity. Arch Ophthalmol. 1986; 104(5):702-5. DOI: 10.1001/archopht.1986.01050170092029. View

Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wiedon A, Wilhelm H . Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study. Health Qual Life Outcomes. 2016; 14(1):132. PMC: 5029004. DOI: 10.1186/s12955-016-0536-1. View

Friedman D, OColmain B, Munoz B, Tomany S, McCarty C, de Jong P . Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122(4):564-72. DOI: 10.1001/archopht.122.4.564. View

10.

Toprak A, Eser E, Guler C, Baser F, Mayali H . Cross-validation of the Turkish version of the 25-item National Eye Institute Visual Functioning Questionnaire (NEI-VFQ 25). Ophthalmic Epidemiol. 2005; 12(4):259-69. DOI: 10.1080/09286580590967763. View

11.

Komarova T, Vitovska O, Komisarenko J, Kohan V . AGE-RELATED MACULAR DEGENERATION - CURRENT STATE OF THE PROBLEM AND PROPHYLAXIS METHODS. Wiad Lek. 2021; 74(3 cz 2):767-772. View

12.

Tuuminen R, Uusitalo-Jarvinen H, Aaltonen V, Hautala N, Kaipiainen S, Laitamaki N . The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. Acta Ophthalmol. 2017; 95(A105 Suppl):1-9. DOI: 10.1111/aos.13501. View

13.

Dogra A, Narang R, Narang J . Recent Advances in Nanotherapeutic Interventions for the Treatment of Alzheimer's Disease. Curr Pharm Des. 2020; 26(19):2257-2279. DOI: 10.2174/1381612826666200422092620. View

14.

Cui Y, Zhang L, Zhang M, Yang X, Zhang L, Kuang J . Prevalence and causes of low vision and blindness in a Chinese population with type 2 diabetes: the Dongguan Eye Study. Sci Rep. 2017; 7(1):11195. PMC: 5593882. DOI: 10.1038/s41598-017-11365-z. View

15.

Jelin E, Wisloff T, Jorstad O, Heiberg T, Moe M . Patient-reported outcome measures in the management of neovascular age-related macular degeneration: a 1-year prospective study. BMJ Open Ophthalmol. 2019; 4(1):e000353. PMC: 6797267. DOI: 10.1136/bmjophth-2019-000353. View

16.

Mitchell P, Liew G, Gopinath B, Wong T . Age-related macular degeneration. Lancet. 2018; 392(10153):1147-1159. DOI: 10.1016/S0140-6736(18)31550-2. View

17.

Wong W, Su X, Li X, Cheung C, Klein R, Cheng C . Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2):e106-16. DOI: 10.1016/S2214-109X(13)70145-1. View

18.

Suner I, Kokame G, Yu E, Ward J, Dolan C, Bressler N . Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009; 50(8):3629-35. DOI: 10.1167/iovs.08-3225. View

19.

Bhisitkul R . Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006; 90(12):1542-7. PMC: 1857529. DOI: 10.1136/bjo.2006.098426. View

20.

Mangione C, Lee P, Pitts J, Gutierrez P, Berry S, Hays R . Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998; 116(11):1496-504. DOI: 10.1001/archopht.116.11.1496. View